Loading patent…
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Servic, Universite De Liege, Centre Hospitalier Universitaire De Liege
InventorsAlbert Beckers, Adrian Francis Daly, Fabio Rueda Faucz, Constantine A. Stratakis, Giampaolo Trivellin
Estimating the term…
The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.
A non-human transgenic animal, comprising an expressed transgene encoding GPR101.
A method of increasing body mass and/or body size of a livestock comprising:
Dependencies are inferred from the claim text.